Dapansutrile (OLT1177) is defined by its novel, specific NLRP3 inflammasome inhibition, demonstrating consistent mechanisms and broad therapeutic applicability across inflammatory diseases, including gouty arthritis (Marchetti et al., 2018b), neurological disorders (Murda et al., 2022), and cardiovascular diseases (Wohlford et al., 2020). Here, NLRP3 is linked to gout.